Last reviewed · How we verify
Dexamethasona, Idarubicine, ARA-C, Methotrexate
This is a combination chemotherapy regimen that uses a corticosteroid, an anthracycline topoisomerase II inhibitor, a nucleoside antimetabolite, and a folate antagonist to kill rapidly dividing leukemic cells through multiple mechanisms.
This is a combination chemotherapy regimen that uses a corticosteroid, an anthracycline topoisomerase II inhibitor, a nucleoside antimetabolite, and a folate antagonist to kill rapidly dividing leukemic cells through multiple mechanisms. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL).
At a glance
| Generic name | Dexamethasona, Idarubicine, ARA-C, Methotrexate |
|---|---|
| Sponsor | PETHEMA Foundation |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone is a corticosteroid that reduces inflammation and promotes apoptosis in leukemic cells. Idarubicine intercalates DNA and inhibits topoisomerase II, causing DNA damage. ARA-C (cytarabine) is incorporated into DNA as a false nucleotide, disrupting replication. Methotrexate inhibits dihydrofolate reductase, blocking nucleotide synthesis. Together, these agents target acute leukemia cells through complementary cytotoxic pathways.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Mucositis
- Nausea and vomiting
- Infection
- Cardiotoxicity (idarubicine-related)
- Hepatotoxicity
- Neurotoxicity (methotrexate-related)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: